Skip to content

Neovascularization Embolisation for Knee Osteoarthritis.(NEO)

Novel Transcatheter Arterial Embolization for Treatment of Knee Osteoarthritis: a Randomized Sham-controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03884049
Acronym
NEO
Enrollment
58
Registered
2019-03-21
Start date
2019-06-05
Completion date
2023-01-30
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee

Keywords

ranscatheter, embolization, osteoarthritis, arterial

Brief summary

In this double blind randomized sham controlled study the investigators want to establish the efficacy of transcatheter arterial embolization of neovessels for patients with symptomatic mild to moderate knee osteoarthritis after 4 months compared to a sham-embolization.

Detailed description

Rationale: Transcatheter arterial embolization has recently been proposed as an efficacious therapy for therapy-resistant osteoarthritis of the knee, providing substantial pain reduction at short-term as well as long-term follow-up up till 4 years. A potential working mechanism of treatment effect is that the normalization of the amount of blood vessels and blood flow achieved by embolization reduces inflammation, resulting in pain reduction Objective: The main objective is to assess whether transcatheter arterial embolization of neovessels in patients with symptomatic knee OA results in significant pain reduction after 4 months compared to sham treatment. The investigators hypothesize that novel transcatheter arterial embolization of neovessels is a feasible, effective, and safe treatment for patients with symptomatic radiographic knee OA, resulting in significant improvement of pain symptoms in a period of 4 months follow-up compared to sham embolization. Secondary objectives are 1. to assess whether reduction of neovessels is related to pain relief, 2. to explore whether decrease of inflammation is a mediating factor between neovessel reduction and pain relief, 3. to assess whether transcatheter arterial embolization reduction of neovessels decreases peripheral and central pain sensitization and 4. to assess whether transcatheter arterial embolization improve the outcome at 1, 4, 8 and 12 months compared to placebo of the: ICOAP, painDETECT, EQ-5D-5L questionnaires and NRS for pain.

Interventions

PROCEDUREEmbolization

transcatheter arterial embolization of neovessels around the knee

Sham transcatheter arterial embolization of neovessels in the knee

Sponsors

William Cook Europe
CollaboratorINDUSTRY
Stichting Coolsingel
CollaboratorUNKNOWN
Erasmus Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Double blinded

Intervention model description

Double-blinded randomized placebo-controlled clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age.≥18 years * Knee pain for a duration of ≥ 6 months * Knee pain (numeric rating scale ≥4 - ≤8) on at least half of the days in the preceding month at time of inclusion. * There is insufficient response of conservative treatment for at least 6 months * Radiographic knee osteoarthritis (radiographic Kellgren and Lawrence grade 1-3) Exlusion criteria: * Contra-indications for MRI (e.g. metallic foreign bodies, etc.) * Contra-indications for angiography * Renal insufficiency, checked with blood sample test (GFR \< 30 ml/min/1, 73 m2); * Known allergy to contrast agents; * Patient has known allergies to barium sulfate, 3-aminopropyltrialkoxysilane, polyphosphazene * Women who are pregnant or lactating * Intermittent claudication of affected limb * Intra articular injections in the ipsilateral knee less than 6 months ago * On the waiting list for joint replacement surgery * Amitriptyline usage. * Patient has known allergies to barium sulfate, 3-aminopropyltrialkoxysilane, polyphosphazene. * Insufficient command of the Dutch or English language. * Legally incompetent adults.

Design outcomes

Primary

MeasureTime frameDescription
KOOS pain sub score4 monthsKOOS pain sub score after 4 months

Secondary

MeasureTime frameDescription
Total KOOS1,4,8,12 month(s)Total KOOS result
painDETECT questionnaire1,4,8,12 month(s)painDETECT questionnaire results
ICOAP questionnaire1,4,8,12 month(s)ICOAP questionnaire results
Knee MRI1 and 4 month(s)Knee MRI scan results
EQ-5D-5L questionnaire1,4,8,12 month(s)EQ-5D-5L questionnaire results
Pressure pain threshold testing1,4,8,12 month(s)Pressure pain threshold testing results
Pain Score 0-10 Numerical Rating Scale (NRS)1,4,8,12 month(s)The Numeric Pain Rating Scale (NPRS) is a unidimensional measure of pain intensity in adults. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine or worst pain imaginable).

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026